NCT04171141 : A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07062119 IN PATIENTS WITH ADVANCED GASTROINTESTINAL TUMORS

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

OnePhase One

18+Age Over 18

Advanced CancersCancer LocationMulti-Cancer
Trial

Systemic therapy | Bowel (colorectum),Stomach and upper gastrointestinal tractColorectum,Oesophagus,Stomach

Trial Overview Read MoreRead more

This phase I trial is trying to understand how safe and tolerable a new targeted therapy drug (PF-07062119) is in people with selected advanced or metastatic gastrointestinal cancers.
 

This trial is treating patients with colorectal, stomach and oesophageal cancers.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have been diagnosed with cancer, but have not received any treatment.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • Your cancer has not spread to other parts of the body.
  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07062119 IN PATIENTS WITH ADVANCED GASTROINTESTINAL TUMORS

Commercial Sponsor

Pfizer

Summary

This is a non-randomised, multi-arm dose escalation and dose expansion study of PF-07062119 administered as a single agent in sequential dose levels, and then in combination with anti-programmed cell death-1 protein (anti-PD-1), and in combination with an anti-vascular endothelial growth factor (anti-VEGF). This study contains 2 parts, dose escalation with a single agent (Part 1A) and then dose finding with PF-07062119 in combination with anti-PD-1 and in combination with anti-VEGF (Part 1B), followed by dose expansion arms as a single agent and PF-07062119 in combination with anti-PD-1 and in combination with anti-VEGF (Part 2).

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Enquiries Line Coordinator
clinicaltrials.enquiries@petermac.org
03 8559 7456 (9am-2pm, Mon-Fri)

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next